Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Oral Edaravone (TTYP01) in Healthy Adults
NCT04370431Phase 1Completed
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of edaravone in amyotrophic lateral sclerosis (ALS) and acute ischemic stroke (AIS) (6 arms). Primary endpoints: Adverse events up to 4 weeks, Change in hematology parameters (hemoglobin, hematocrit, RBC, WBC, platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils) and 4 more. Started Apr 2020; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)acute ischemic stroke (AIS)
Beyond the preview
Go deeper on NCT04370431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04370431.